Ovarian Cancer at an Inflection Point: Quantifying the Burden, Closing Gaps, and Accelerating Next-Generation Therapies avatar David Alvaro, Ph.D.

https://www.pharmasalmanac.com/articles/ovarian-cancer-at-an-inflection-point-quantifying-the-burden-closing-gaps-and-accelerating-next-generation-therapies Ovarian cancer remains the most lethal gynecologic malignancy, and its global burden is increasing at an alarming rate. Clinical management has advanced in the past decade, with the traditional backbone of cytoreductive surgery and platinum/taxane chemotherapy now complemented by maintenance strategies, such as PARP inhibitors and bevacizumab, particularly for biomarker-selected populations. Yet resistance and relapse remain common, driving the need for new modalities. A rapidly evolving therapeutic landscape includes antibody–drug conjugates (ADCs), inhibitors of the additional pathways, novel approaches to DNA damage beyond PARP, and rational immuno-oncology combinations. Precision medicine strategies are also gaining ground in low-grade serous, clear cell, and platinum-resistant tumors. Closing the survival gap will require coordinated action: investment in data-linked screening trials, earlier and broader molecular typing, equitable access to testing and therapies, adaptive trial platforms, and systematic real-world evidence capture to guide practice and accelerate discovery.